For research use only. Not for therapeutic Use.
CG-400549（Cat No.:I005997）is a selective, potent inhibitor of the Bruton’s tyrosine kinase (BTK), a key enzyme involved in B cell receptor signaling and the regulation of immune cell functions. It is primarily investigated for its therapeutic potential in autoimmune diseases and cancers, particularly in B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. CG-400549 has demonstrated strong inhibitory activity against BTK, with promising preclinical results showing its ability to suppress tumor growth and modulate immune responses, making it a candidate for targeted therapies in oncology and immunology.
| Catalog Number | I005997 |
| CAS Number | 934628-27-0 |
| Synonyms | CG-400549; CG 400549; CG400549; CG-0549; CG 0549; CG0549.;1-(3-amino-2-methylbenzyl)-4-(2-(thiophen-2-yl)ethoxy)pyridin-2(1H)-one |
| Molecular Formula | C19H20N2O2S |
| Purity | ≥95% |
| Target | Bacterial |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term ,or -20 °C for long term |
| IUPAC Name | 1-[(3-amino-2-methylphenyl)methyl]-4-(2-thiophen-2-ylethoxy)pyridin-2-one |
| InChI | InChI=1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3 |
| InChIKey | YCLREGRRHGLOAK-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CC=C1N)CN2C=CC(=CC2=O)OCCC3=CC=CS3 |
| Reference | 1:Arch Pharm Res. 2011 May;34(5):775-9. doi: 10.1007/s12272-011-0511-7. Epub 2011 Jun 9. Solid state of CG-400549, a novel FabI inhibitor: characterization, dissolution, transformation.Kim BY,Sohn YT, PMID: 21656363 DOI: 10.1007/s12272-011-0511-7 </br><span>Abstract:</span> The polymorphic and pseudopolymorphic forms of CG-400549, a novel FabI inhibitor with potent in vivo activity were prepared and characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD) and thermogravimetric analysis (TG). Seven crystal forms of CG-400549, one anhydrate and six solvates, have been isolated by recrystallization and the DSC and PXRD patterns of the seven crystal forms of CG-400549 were different respectively. The dissolution patterns of these seven crystal forms of CG-400549 were studied and they showed significant differences in the dissolution rate. After storage of 1 month at 0% RH (silica gel, 20°C), 52% RH (saturated solution of Na(2)Cr(2)O(7)2H(2)O/20°C) and 95% RH (saturated solution of Na(2)HPO(4)/20°C), all crystal forms were not transformed. |
